ISRCTN16926948已完成未知
Safety and tolerability of Yaq-001 in patients with cirrhosis
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- Yaqrit Ltd
- 入组人数
- 56
研究概览
简要总结
2021 Abstract results in http://dx.doi.org/10.1136/gutjnl-2021-BASL.9 (added 18/02/2022)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Male and female patients
- •2. Aged 18 years old or older at screening
- •3. Clinical diagnosis of cirrhosis for any cause. Liver biopsy is not required
- •4. Cirrhotic patients with diuretic-responsive ascites and Child-Pugh score = 7-11 inclusive
- •5. Abstinence from alcohol for at least 4 weeks prior to screening
排除标准
- •1. Refusal or inability (lack of capacity) to give informed consent
- •2. Prohibited medication within 4 weeks before the start of the study treatment: all oral antibiotics, immunosuppressants, long acting benzodiazepines or barbiturates and antiviral medication
- •3. Change in dose of proton pump inhibitor therapy within 4 weeks before the start of the study treatment
- •4. Patients with once daily medications in which orocaecal transit time is greater than 10 hours
- •5. Patients requiring medication in which the dosing schedule is three times per day or greater
- •6. Antiviral therapy for hepatitis C within 3 months prior to screening
- •7. Hospital admission for liver-related indication for at least 4 weeks (except paracentesis)
- •8. BMI > 35 or BMI < 18
- •9. Clostridium Difficile diarrhoea within 4 weeks before the start of the study treatment
- •10. Uncontrolled infection (chronic viral hepatitis is not an exclusion criterion)
- •11. Human immunodeficiency virus
- •12. Presence of a transjugular intrahepatic portosystemic shunt (TIPSS)
- •13. Participation in any clinical study of an investigational medicinal product within 30 days of five half-lives of the investigational product, whichever is longer
- •14. Presence of clinically relevant cardiovascular, pulmonary, gastro-intestinal, renal, hepatic, metabolic, haematological, neurological, psychiatric, systemic, ocular, gynaecologic or any acute infection disease or signs of acute illness that, in the opinion of the investigator, might compromise the patient’s safe participation in the trial and/or result in a WHO performance status of 2 or more
- •15. Presence of the history of cancer within the past 5 years with exception of hepatocellular carcinoma within Milan criteria, adequately treated localised basal cell carcinoma of the skin, in situ cervical carcinoma or solid malignancy surgical excised in total without recurrence for five years
- •16. Women of child bearing potential (only postmenopausal women or with surgical sterilization will be included)
研究者
相似试验
撤回
不适用
Safety and Tolerability of Yaq-001 in Patients With Non-Alcoholic SteatohepatitisNon-Alcoholic SteatohepatitisNCT03962608Yaqrit Ltd
终止
不适用
Safety and Tolerability of Yaq-001 in Patients With CirrhosisLiver CirrhosisNCT03202498Yaqrit Ltd31
已完成
1 期
Dose Escalation and Cohort Expansion Study of YS-ON-001 in Patients With Advanced Solid TumorsCancerNCT03131765Yisheng Biopharma (Singapore) Pte. Ltd.31
已完成
1 期
An Phase I Study of YY001 in Patients with Advanced Solid TumorsAdvanced Solid TumorNCT06228846Shanghai Yuyao Biotech Co., Ltd.16
进行中（未招募）
1 期
SYN-004 Safety and Tolerability in Allo-HCT SubjectsAcute Graft-Versus-Host Reaction Following Bone Marrow TransplantPrevention of CDI in Adult Patients Being Treated With IV Beta-lactam AntibioticsNCT04692181Theriva Biologics, Inc.36